This phase 1/2 trial assessed HER2 BATs combined with pembrolizumab in metastatic breast cancer, finding the regimen safe and well tolerated with stable disease as the best response in 17 evaluable patients.
Amy Schmachtenberg
Advertisement
Articles by Amy Schmachtenberg
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears Alpha DaRT Trial to Complete Enrollment in Recurrent GBM
2
Belantamab Mafodotin Regimen Yields Enduring Responses in NDMM
3
Arlo-Cel Produces Deep Responses in Pretreated R/R Multiple Myeloma
4
FDA Accepts BLA for Ozekibart in Unresectable or Metastatic Chondrosarcoma
5